Relapsing Forms of Multiple Sclerosis Clinical Trial
— POPOfficial title:
Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program
NCT number | NCT02230969 |
Other study ID # | 105MS401 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | November 12, 2014 |
Est. completion date | January 20, 2022 |
Verified date | September 2022 |
Source | Biogen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS in routine clinical practice. The secondary objectives of this study in this study population are to describe Plegridy prescription and utilization adherence patterns in routine clinical practice; to assess the specific long-term clinical effectiveness of Plegridy in participants with relapsing forms of MS in routine clinical practice; to monitor the safety and tolerability of Plegridy in routine clinical practice by assessing the incidence of adverse events (AEs) of flu-like symptoms (FLS), injection site reactions (ISRs), and AEs (including laboratory abnormalities) leading to treatment discontinuation; to assess the effect of FLS on participant-reported effectiveness of, and satisfaction with, prophylactic management using a FLS-Visual Analog Scale (FLS-VAS); to evaluate the change in health-related quality of life (HRQoL), FLS, FLS-VAS, healthcare resource consumption, and treatment adherence over time.
Status | Completed |
Enrollment | 1208 |
Est. completion date | January 20, 2022 |
Est. primary completion date | January 20, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Patient with MS who is newly, or is currently, prescribed Plegridy according to local label including patients who participated in Study 105MS302 (NCT01332019) or Study 105MS303 (NCT01939002). - Patient willing and able to complete patient-reported outcomes (PRO) with minimal assistance. Key Exclusion Criteria: - Concurrent enrollment in any clinical trial of an investigational product. Participation in non-interventional study can be allowed as long as this participation does not interfere with this protocol or is likely to affect the subject's ability to comply with the protocol. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
Australia | Research Site | Auchenflower | Queensland |
Australia | Research Site | Bedford Park | South Australia |
Australia | Research Site | Camperdown | New South Wales |
Australia | Research Site | Fitzroy | Victoria |
Australia | Research Site | Heidelberg | Victoria |
Australia | Research Site | New Lambton Heights | New South Wales |
Austria | Research Site | Linz | |
Austria | Research Site | Vienna | |
Canada | Research Site | Barrie | Ontario |
Canada | Research Site | Calgary | Alberta |
Canada | Research Site | Cambridge | Ontario |
Canada | Research Site | Gatineau | Quebec |
Canada | Research Site | Halifax | Nova Scotia |
Canada | Research Site | Saint John | New Brunswick |
Canada | Research Site | Sydney | Nova Scotia |
Canada | Research Site | Toronto | Ontario |
Denmark | Research Site | Esbjerg | |
Denmark | Research site | Glostrup | |
Denmark | Research Site | Sonderborg | |
France | Research Site | Gonesse | |
France | Research Site | La Seyne sur Mer | Var |
France | Research Site | Le Mans cedex 9 | Sarthe |
France | Research Site | Mantes La Jolie cedex | Yvelines |
France | Research Site | Montpellier | Herault |
France | Research Site | Nimes | Gard |
France | Research Site | Poitiers cedex | Vienne |
France | Research Site | Rennes cedex 09 | Ille Et Vilaine |
France | Research Site | Saint Malo cedex | Ille Et Vilaine |
France | Research Site | Toulouse cedex 9 | Haute Garonne |
Germany | Research Site | Aachen | Nordrhein Westfalen |
Germany | Research Site | Aalen | Baden Wuerttemberg |
Germany | Research Site | Altenburg | Thueringen |
Germany | Research Site | Bad Homburg | Hessen |
Germany | Research Site | Bamberg | Bayern |
Germany | Research Site | Berlin | |
Germany | Research Site | Berlin | |
Germany | Research Site | Berlin | |
Germany | Research Site | Bonn | Nordrhein Westfalen |
Germany | Research Site | Butzbach | Hessen |
Germany | Research Site | Chemnitz | Sachsen |
Germany | Research Site | Duesseldorf | Nordrhein Westfalen |
Germany | Research Site | Erfurt | Thueringen |
Germany | Research Site | Frankfurt | Hessen |
Germany | Research Site | Freiburg | Baden Wuerttemberg |
Germany | Research Site | Gelnhausen | Hessen |
Germany | Research Site | Gottingen | Niedersachsen |
Germany | Research Site | Hamburg | |
Germany | Research Site | Hamburg | |
Germany | Research Site | Heidenheim | Baden Wuerttemberg |
Germany | Research Site | Itzehoe | Schleswig Holstein |
Germany | Research Site | Jena | Thueringen |
Germany | Research Site | Kandel | Rheinland Pfalz |
Germany | Research Site | Kassel | Hessen |
Germany | Research Site | Kiel | Schleswig Holstein |
Germany | Research Site | Koeln | Nordrhein Westfalen |
Germany | Research Site | Ladenburg | Baden Wuerttemberg |
Germany | Research Site | Leipzig | Sachsen |
Germany | Research Site | Ludwigshafen | Rheinland Pfalz |
Germany | Research Site | Muenchen | Bayern |
Germany | Research Site | Pforzheim | Baden Wuerttemberg |
Germany | Research Site | Regensburg | Bayern |
Germany | Research Site | Regensburg | Bayern |
Germany | Research Site | Ruedersdorf | Brandenburg |
Germany | Research Site | Sande | Niedersachsen |
Germany | Research Site | Siegen | Nordrhein Westfalen |
Germany | Research Site | Stade | Niedersachsen |
Germany | Research Site | Stadtroda | Thueringen |
Germany | Research Site | Stuttgart | Baden Wuerttemberg |
Ireland | Research Site | Dublin | |
Italy | Research Site | Bergamo | |
Italy | Research Site | Cagliari | |
Italy | Research Site | Catanzaro | |
Italy | Research Site | Firenze | |
Italy | Research Site | Genova | |
Italy | Research Site | Messina | |
Italy | Research Site | Milano | |
Italy | Research Site | Napoli | |
Italy | Research Site | Roma | |
Italy | Research Site | Roma | |
Italy | Research Site | Roma | |
Netherlands | Research Site | Blaricum | |
Netherlands | Research Site | Breda | |
Netherlands | Research Site | Hoorn | |
Portugal | Research Site | Guimarães | |
Portugal | Research Site | Setúbal | |
Spain | Research Site | Cadiz | |
Spain | Research Site | Cordoba | |
Spain | Research Site | Málaga | |
Spain | Research Site | Sevilla | |
Spain | Research Site | Sevilla | |
Switzerland | Research Site | Aarau | |
Switzerland | Research Site | Basel | |
Switzerland | Research Site | Bern | |
Switzerland | Research Site | Luzern | |
United Kingdom | Research Site | Glasgow | Strathclyde |
United Kingdom | Research Site | Inverness | Highland Region |
United Kingdom | Research Site | Irvine | Ayrshire |
United Kingdom | Research Site | Leicester | Leicestershire |
United Kingdom | Research Site | London | Greater London |
United Kingdom | Research Site | Salford | Greater Manchester |
United Kingdom | Research Site | Swansea | |
United Kingdom | Research Site | Truro | Cornwall |
United States | Research Site | Albuquerque | New Mexico |
United States | Research Site | Atlanta | Georgia |
United States | Research Site | Basalt | Colorado |
United States | Research Site | Bedford | Texas |
United States | Research Site | Berkeley | California |
United States | Research Site | Boston | Massachusetts |
United States | Research Site | Buffalo | New York |
United States | Research Site | California City | California |
United States | Research Site | Charlotte | North Carolina |
United States | Research Site | Colorado Springs | Colorado |
United States | Research Site | Dayton | Ohio |
United States | Research Site | Dayton | Ohio |
United States | Research Site | Delray Beach | Florida |
United States | Research Site | Des Moines | Iowa |
United States | Research Site | Freehold | New Jersey |
United States | Research Site | Gilbert | Arizona |
United States | Research Site | Golden Valley | Minnesota |
United States | Research Site | Great Falls | Montana |
United States | Research Site | Hanford | California |
United States | Research Site | Hickory | North Carolina |
United States | Research Site | Homewood | Alabama |
United States | Research Site | Indianapolis | Indiana |
United States | Research Site | Iowa City | Iowa |
United States | Research Site | Knoxville | Tennessee |
United States | Research Site | Lebanon | New Hampshire |
United States | Research Site | Lexington | Massachusetts |
United States | Research Site | Louisville | Kentucky |
United States | Research Site | Milwaukee | Wisconsin |
United States | Research Site | New Hyde Park | New York |
United States | Research Site | New Orleans | Louisiana |
United States | Research Site | New York | New York |
United States | Research Site | Oklahoma City | Oklahoma |
United States | Research Site | Oklahoma City | Oklahoma |
United States | Research Site | Orange | California |
United States | Research Site | Pittsburgh | Pennsylvania |
United States | Research Site | Port Royal | South Carolina |
United States | Research Site | Portland | Oregon |
United States | Research Site | Raleigh | North Carolina |
United States | Research Site | Richmond | Virginia |
United States | Research Site | Saint Louis | Missouri |
United States | Research Site | Salt Lake City | Utah |
United States | Research Site | Scarborough | Maine |
United States | Research Site | Schaumburg | Illinois |
United States | Research Site | Scottsdale | Arizona |
United States | Research Site | Southfield | Michigan |
United States | Research Site | Staten Island | New York |
United States | Research Site | Virginia Beach | Virginia |
United States | Research Site | Washington | District of Columbia |
United States | Research Site | Washington | District of Columbia |
United States | Research Site | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Biogen |
United States, Australia, Austria, Canada, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety as measured by the incidence proportion of SAEs | Up to 5 years | ||
Primary | Safety as measured by the incidence rate of SAEs | Up to 5 years | ||
Primary | Clinical no evidence of disease activity (NEDA) as measured by the proportion of participants with no relapses | Up to 5 years | ||
Primary | Clinical NEDA as measured by the proportion of participants with no disability progression | Up to 5 years | ||
Secondary | Prescription and utilization patterns as measured by prescribed dosing frequency | Up to 5 years | ||
Secondary | Prescription and utilization patterns as measured by duration of Plegridy use | Up to 5 years | ||
Secondary | Prescription and utilization patterns as measured by the primary reason for discontinuation of Plegridy | Up to 5 years | ||
Secondary | Relapse activity as measured by annualized relapse rate (ARR) | Up to 5 years | ||
Secondary | Relapse activity as measured by time to first relapse | Up to 5 years | ||
Secondary | Relapse activity as measured by the proportion of participants with relapse | Up to 5 years | ||
Secondary | Relapse activity as measured by the distribution of the number of relapses | Up to 5 years | ||
Secondary | Disability progression as measured by the proportion of participants with sustained progression for at least six months | Disability progression measured by the Expanded Disability Status Scale (EDSS). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. Participants with confirmed progression of disability in EDSS physical functional system scores will be defined as those who meet one of the following criteria: an increase of = 1 point from baseline system score of = 1 or an increase of = 2 points from baseline system score of 0 in at least 2 physical functional systems, or an increase of = 2 points from baseline system score of = 1 or an increase of = 3 points from baseline system score of 0 in any 1 physical functional system. Worsening must be confirmed on a subsequent examination using the same criterion in the same functional system(s) at least 6 months later. | Up to 5 years | |
Secondary | Disability progression as measured by the time to sustained disability progression for at least six months | Up to 5 years | ||
Secondary | Incidence proportion of non-serious AEs leading to treatment discontinuation | Up to 5 years | ||
Secondary | Incidence rate of non-serious AEs leading to treatment discontinuation | Up to 5 years | ||
Secondary | Impact of the severity of FLS on the ability to successfully manage symptoms via prophylaxis as measured by the participant-reported FLS-VAS | Up to 5 years | ||
Secondary | Changes in FLS assessment and FLS-VAS over time | Baseline to 5 years | ||
Secondary | Changes in EuroQoL EQ-5D, 3-level (EQ-5D-3L) score over time | The EQ-5D-3L is a standardized instrument for use as a measure of health outcome. It is a health questionnaire that consists of 2 pages - the EQ-5D descriptive system (page 2) and the EQ visual analogue scale (EQ VAS) (page 3). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. | Baseline to 5 years | |
Secondary | Treatment adherence as measured by changes in adherence over time as reported in the treatment adherence questionnaires | Where pen/syringe collection is locally allowed, treatment adherence will also be assessed by the proportion of used auto-injector pens/pre-filled syringes out of the total number of pens/syringes prescribed. | Baseline to 5 years | |
Secondary | Frequency of MS-related and non-MS-related physician visits, specialists' visits, use of physiotherapy, hospitalizations and lengths of stay, and emergency room/department visits | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01201356 -
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 3 | |
Suspended |
NCT04909502 -
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT05083923 -
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
|
Phase 3 | |
Withdrawn |
NCT02428218 -
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
|
Phase 3 | |
Completed |
NCT01873417 -
Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States
|
Phase 4 | |
Completed |
NCT04676555 -
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
|
||
Recruiting |
NCT05798520 -
A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT00424788 -
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
|
Phase 0 | |
Recruiting |
NCT06251986 -
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
|
||
Completed |
NCT02097849 -
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
|
Phase 2 | |
Completed |
NCT01903291 -
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
|
N/A | |
Completed |
NCT01216072 -
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 4 |